Fig. 1

Prevalence and titre of SARS-CoV-2 spike-specific antibody response in patients with CLL following dual COVID-19 vaccination. A Proportion of donors who develop a positive antibody response following dual vaccination. HD = Healthy donors; CLL = CLL-VR patient cohort. B (i) Antibody titres in participants with a positive antibody response. Donors with serological evidence of previous natural SARS-CoV-2 infection (previous exposure; PE) were excluded (p =  < 0.0001). (ii) Antibody titres in CLL patients in relation to history of previous natural exposure (PE) or no previous exposure (NPE) (p < 0.0001). Cut off for positive response is indicated by dotted line). (iii) Antibody titres in paired serum samples from patients with CLL following first and second vaccine. Red lines indicate patients with PE. C (i) Proportion of patients with CLL who develop a positive antibody response following dual vaccination with either the BNT162b2 or ChAdOx1 vaccine. (ii) Antibody titres in CLL patients in relation to vaccine subtype